[U.S. SOCCER] U.S. women's goalkeeper Hope Solo has received a public warning from the U.S. Anti-Doping Agency (USADA) after testing positive for a banned substance in a doctor-prescribed medicine she took for premenstrual purposes. The warning does not affect her eligibility for this summer’s Olympics, according the U.S. Soccer Federation.
The positive result came from an out-of-competition urine sample Solo provided on June 15. A statement released by the U.S. Soccer Federation (USSF) reads:
“After discussions with Hope, we fully support her clarification that the positive test for Canrenone was due to the use of a prescribed medication from a personal doctor for premenstrual purposes and not related to performance enhancement in any way. We fully cooperated with USADA during the disciplinary process to ensure it could be resolved quickly. Hope has accepted the public warning for her rule violation.”
Solo helped the USA win the gold medal at the last Olympic Games, in 2008. She also played for the USA at the last two World Cups, in 2007 and 2011. In a statement released through the USSF, Solo said:
"I took a medication prescribed by my personal doctor for premenstrual purposes that I did not know contained a diuretic. Once informed of this fact, I immediately cooperated with USADA and shared with them everything they needed to properly conclude that I made an honest mistake, and that the medication did not enhance my performance in any way.
“As someone who believes in clean sport, I am glad to have worked with USADA to resolve this matter and I look forward to representing my country at the 2012 Olympic Games in London."
Diuretics are banned because they can help with weight loss and could be used to speed up the elimination of drugs from the system.
“Canrenone is classified as a Specified Substance, and therefore the presence of Canrenone in an athlete’s sample can result in a reduced sanction,” read a statementby the USADA. “Solo was taking a prescribed medication, in a therapeutic dose under the care of a physician. The medication when metabolized resulted in the adverse analytical finding.”
“As in all cases, we thoroughly investigate the circumstances and always do what is fair and right for clean athletes and the integrity of sport,” stated Travis T. Tygart, USADA Chief Executive Officer.